Gupta et al. have recently reported the use of fludarabine, cyclophosphamide and alemtuzumab and unrelated allogeneic transplantation in a series of seven patients with severe aplastic anaemia (SAA). 1 All patients achieved sustained engraftment, with a median follow-up of 289 days (range 211-995). Treatment-related mortality (TRM) occurred in two cases: one with adenovirus disease, one with combined extensive chronic GvHD and cytomegalovirus infection. The report highlights the potential advantages of reduced-intensity conditioning in this context, where TRM has been traditionally high. We report our experience of one case of SAA where use of this reduced-intensity regimen was followed by secondary graft failure and severe autoimmune haemolytic anaemia (AIHA) and in which salvage with second unrelated transplant using conventional intensity conditioning resulted in long-term remission of both SAA and AIHA.
A 16-year-old female presented with SAA in March 2003 and subsequently failed two lines of treatment, namely cyclosporin with horse anti-lymphocyte globulin (unable to tolerate) and rabbit anti-thymocyte globulin (transient response only). In October 2003, the patient underwent treatment with alemtuzumab 0.2 mg/kg (10 mg) i.v. daily for 5 days, fludarabine 30 mg/m 2 i.v. for 5 days and cyclophosphamide at 300 mg/m 2 i.v. for 4 days followed by transplantation with allogeneic bone marrow (3.57 Â 10 8 /kg total nucleated cell dose) from a 10/10 HLA molecularly matched unrelated donor. GvHD prophylaxis was with cyclosporin, which commenced at day À1 with a therapeutic target range of 200-250 ng/l. Neutrophil engraftment 41 Â 10 9 /l was achieved on day þ 21 and platelet engraftment 450 Â 10 9 /l was achieved on day þ 13. Early post transplant complications included skin erythema consistent clinically with GvHD (grade I), which responded promptly to a tapering course of corticosteroids. The patient was discharged on day þ 24. Bone marrow aspirate and trephine biopsy at 3 months demonstrated established tri-lineage haematopoiesis, with fluorescence in situ hybridization analysis showing a male cell population in 98% of cells examined.
The patient re-presented in March 2004 (day þ 177) with fever, sore throat and muscular aches associated with a haemoglobin of 9.9 g/dl, white cell count of 1.0 Â 10 9 /l (neutrophil count of 0.1 Â 10 9 /l) and a platelet count of 185 Â 10 9 /l. A diagnosis of possible marrow suppression secondary to a recent viral illness was initially made. Treatment with empirical antibiotic therapy, G-CSF and maintenance of cyclosporin level (which was always in the therapeutic range) was instituted. Despite these measures, the patient became progressively pancytopenic, and repeat bone marrow examinations confirmed severe hypoplasia with progressive mixed chimaerism consistent with relapse of SAA. Extensive microbiological screening, including PCR testing, showed no evidence of specific infection, including CMV, EBV, adenovirus, parvovirus and HHV-6.
Subsequently, the patient developed catastrophic direct antiglobulin test (DAT) positive haemolysis. Immunohaematological workup confirmed the DAT was strongly positive for IgG, IgM, C3c and C3d. The plama contained warm auto-antibodies only, showing evidence of anti-D or LW specificity. The haemolysis continued despite treatment with corticosteroids, intravenous immunoglobulin, plasma exchanges and rituximab. The lowest recorded haemoglobin was 3.5 g/dl (post transfusion) and the highest bilirubin level was 1003 mmol/l, and the patient developed oliguric renal failure (creatinine and urea peaking at 372 mmol and 42.2 mmol/l, respectively). Supportive management included transfusion of 6-8 units of blood per day and renal support with haemofiltration with added plasma filtration with molecular adsorbents recirculation system to remove the excess bilirubin. Resolution of haemolysis was observed after the additional administration of alemtuzumab (10 mg per day for 7 days), and subsequently the patient stabilized but remained pancytopenic with a neutrophil count o0.1 Â 10 9 /l and a platelet count o10 Â 10 9 /l. A decision was made to perform a second transplant procedure as a means of treating both life-threatening SAA and AIHA. In planning the treatment, a decision was made to avoid fludarabine in the conditioning regimen based on its association with AIHA and to use a conventional conditioning regimen. In June 2004, the patient received cyclophosphamide 50 mg/kg for 4 days and alemtuzumab (one dose at 20 mg with three subsequent 10 mg doses) followed by bone marrow transplant (1.62 Â 10 8 /kg total nucleated cell dose) from the original donor. Engraftment was rapid (neutrophils 41 Â 10 was complicated by acute GvHD of the skin (grade I) responsive to steroids. Trilineage engraftment with normal full blood counts has been sustained for over 22 months post second transplant with 100% donor cell population by cytogenetics and 96% donor molecular chimaerism on bone marrow examination at 20 months. The main complication has been limited chronic GvHD of the skin, and the patient continues on cyclosporin, mycophenolate mofetil, a reducing course of corticosteroids, along with prophylactic antibiotics. There have been no major infective episodes and no recurrence of the autoimmune haemolysis. Quality of life is good, Karnofsky score is 90 and the patient is working.
In summary, this case highlights the potential of graft failure with fludarabine-based reduced-intensity conditioning for transplantation in SAA. Moreover, the occurrence of catastrophic, treatment-resistant AIHA in the post transplant course might be related to fludarabine. 2 Although the use of non-myeloablative conditioning may represent a worthwhile approach to reduce mortality and morbidity of unrelated transplantation, occasionally patients may fail with this approach and a second transplant using a more intensive conditioning regimen, such as cyclophosphamide 200 mg/kg, combined with serotherapy should be considered in this context. Greater immuno-and myeloablation and chronic GvHD (with a graft versus autoimmune effect against the autoimmune diathesis) may have been important factors in achieving sustained remission of SAA and AIHA. 3 
